, Volume 21, Issue 13, pp 927–940 | Cite as

Quality of life in patients with rheumatoid arthritis

Which Drugs Might Make a Difference?
  • Barbara Blumenauer
  • Ann Cranney
  • Jennifer Clinch
  • Peter Tugwell
Review Article


Rheumatoid arthritis (RA) is a chronic, disabling, inflammatory polyarthritis that affects patient well-being and QOL. Many disease-modifying antirheumatic drugs (DMARDs) are available for treating RA but patients are often refractory to treatment. The goal of treatment is to improve both general health and health-related QOL. Generic and disease-specific instruments exist to measure QOL. Using these instruments, one can determine if QOL improves with treatment. If the minimal clinically important difference (MCID) for the instrument is known, one can determine if the change is clinically significant.

The literature was reviewed in a systematic manner to determine which drugs could affect QOL in patients with refractory RA. Refractory RA is poorly defined but we used the definition of failing at least two DMARDs. Methotrexate, leflunomide, cyclosporin, glucocorticoids, etanercept and infliximab clinically and statistically significantly improved QOL in patients with RA. Gold and epoetin-α (erythropoietin) statistically improved QOL in patients with RA but the clinical significance of the improvements could not be determined. These studies were either in non-refractory populations or the refractoriness could not be determined. Further study is required to determine the response of QOL to treatment in patients with refractory RA and instruments with known MCIDs should be used so that the clinical significance of the improvement can be determined.


Rheumatoid Arthritis Infliximab Etanercept Minimal Clinically Important Difference Health Assessment Questionnaire 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Jessie McGowan for her assistance with the literature search for this article. Dr Tugwell is a paid consultant for and has received grants from a variety of pharmaceutical companies. There was no specific funding for this study.


  1. 1.
    Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14–21PubMedCrossRefGoogle Scholar
  2. 2.
    Van de Putte LBA, Kroot EJA, van Riel PLCM. Management of refractory rheumatoid arthritis. Rheumatology 1999; 38 Suppl. 2: 32–4PubMedGoogle Scholar
  3. 3.
    Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35PubMedCrossRefGoogle Scholar
  4. 4.
    Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. J Rheumatol 1997; 24: 1910–5PubMedGoogle Scholar
  5. 5.
    Clinch J, Tugwell P, Wells G, et al. Individualized functional priority approach to the assessment of health related quality of life in rheumatology. J Rheumatol 2001; 28: 445–51PubMedGoogle Scholar
  6. 6.
    Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153: 1337–42PubMedCrossRefGoogle Scholar
  7. 7.
    Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (7): 1478–87PubMedCrossRefGoogle Scholar
  8. 8.
    Fries IF. How may quality of life for rheumatoid arthritis patients be enhanced by current and future treatments? Rheumatology 1999; 38 Suppl. 2: 35–40PubMedGoogle Scholar
  9. 9.
    Buchbinder R, Bombardier C, Yeung M, et al. Which outcome measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1995; 38 (11): 1568–80PubMedCrossRefGoogle Scholar
  10. 10.
    Scott DL, Garrood T. Quality of life measures use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000; 14 (4): 663–87PubMedCrossRefGoogle Scholar
  11. 11.
    Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of lie in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81 (4): 565–78PubMedCrossRefGoogle Scholar
  12. 12.
    Meenan RF, Anderson JJ, Kazis LE, et al. Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure. Arthritis Rheum 1984; 27 (12): 1344–52PubMedCrossRefGoogle Scholar
  13. 13.
    Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelvemonth, placebo-controlled trial. Arthritis Rheum 2000; 43 (3): 506–14PubMedCrossRefGoogle Scholar
  14. 14.
    Pouchot J, Guillemin F, Coste J, and the French Quality of Life Rheumatology Group, et al. Validity, reliability and sensitivity to change of a French version of the arthritis impact measurement scales2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 52–60PubMedGoogle Scholar
  15. 15.
    Tugwell P, Bombardier C, Buchanan WW. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 59–62PubMedCrossRefGoogle Scholar
  16. 16.
    Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051–5PubMedCrossRefGoogle Scholar
  17. 17.
    Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137–41PubMedCrossRefGoogle Scholar
  18. 18.
    Tilley BC, Alarcon GS, Heyse SP, for the MIRA Trial Group, et al. Minocycline in rheumatoid arthritis. A 48-week, double blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81–9PubMedGoogle Scholar
  19. 19.
    Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000; 22: 128–39PubMedCrossRefGoogle Scholar
  20. 20.
    Smolen IS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 (9149): 259–66PubMedCrossRefGoogle Scholar
  21. 21.
    Strand V, Tugwell P, Bombardier C, et al. Function and healthrelated quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42 (9): 1870–8PubMedCrossRefGoogle Scholar
  22. 22.
    Scott DL. Leflunomide improves quality of life in rheumatoid arthritis. Scand J Rheumatol 1999; 28 Suppl. 112: 23–9CrossRefGoogle Scholar
  23. 23.
    Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life. Scand J Rheumatol 1992; 21 Suppl. 95: 29–33CrossRefGoogle Scholar
  24. 24.
    Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142–6PubMedCrossRefGoogle Scholar
  25. 25.
    Lipsky PE, Van Der Heijde DMFM, St Clair EW, for the AntiTumour Necrosis Factor Trial In Rheumatoid Arthritis With Concomitant Therapy Study Group, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602PubMedCrossRefGoogle Scholar
  26. 26.
    Peeters HRM, Jongen-Lavrencic M, Bakker CH, et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999; 18: 201–6PubMedCrossRefGoogle Scholar
  27. 27.
    Murphy EA, Bell AL, Wojtulewski J, et al. Study of erythropoietin in treatment of anemia in patients with rheumatoid arthritis. BMJ 1994; 309: 1337–8PubMedCrossRefGoogle Scholar
  28. 28.
    Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89 (2): 161–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Barbara Blumenauer
    • 1
  • Ann Cranney
    • 1
  • Jennifer Clinch
    • 2
  • Peter Tugwell
    • 1
  1. 1.Ottawa HospitalUniversity of OttawaOttawaCanada
  2. 2.Clinical Epidemiology UnitUniversity of OttawaOttawaCanada

Personalised recommendations